On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic ...

Robert F. Kennedy Jr. and a group of personal injury lawyers have long accused Merck & Co. of “disease mongering” to boost ...

Both are great stocks to buy in the current environment, but which one is the better bet?

Stroke drug developer Argenica Therapeutics plans a second trial to test its novel candidate, in a sector that has few ...

Pfizer Inc. (NYSE:PFE) was among the stocks on Jim Cramer’s radar on Mad Money as he discussed the upcoming earnings. Cramer ...

The misuse of patents by some of the world’s biggest pharma companies to stifle competition is rarely discussed in global ...

Two of the large-cap biopharma companies with best-selling drugs speeding toward the cliff are Merck & Co. (NYSE: MRK) with ...

But GLP-1s are blunt instruments. The longevity benefits they confer are a byproduct of appetite suppression. Loyal’s drug is ...

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

Stocks extended their rally Thursday, even as oil prices gained, amid continued optimism among traders that the fragile two-week ceasefire between the U.S. and Iran could be sustained. The S&P 500 ...